Quick Takeaways
- Roy D. Baynes has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $5,476,321.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Roy D. Baynes
- Location
- San Diego, CA
- Summary
- The estimated net worth of Roy D. Baynes is at least $5,476,321 dollars as of 07 Apr 2026. Roy D. Baynes is the Director of Natera, Inc. and owns shares of Natera, Inc. (NTRA) stock worth about $4.22M. Roy D. Baynes is the Director of Travere Therapeutics, Inc. and owns shares of Travere Therapeutics, Inc. (TVTX) stock worth about $1.24M. Roy D. Baynes is the Director of Atara Biotherapeutics, Inc. and owns shares of Atara Biotherapeutics, Inc. (ATRA) stock worth about $16.9K.
- Signature
- /s/ Elizabeth E. Reed, Attorney-in-Fact
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Roy D. Baynes and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: Natera, Inc. ($4,221,899).
- Past-year value change for that position: -$2,809,689.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Roy D. Baynes
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| NTRA | Natera, Inc. | Director | $4,221,899 | -$2,809,689 | -40% | 30 Jan 2026 |
| TVTX | Travere Therapeutics, Inc. | Director | $1,237,500 | -$330,000 | -21% | 06 Apr 2026 |
| ATRA | Atara Biotherapeutics, Inc. | Director | $16,922 | 23 Jun 2022 | ||
| AARD | Aardvark Therapeutics, Inc. | Director | 11 Jun 2025 | |||
| EIKN | Eikon Therapeutics, Inc. | Chief Medical Officer | 02 Mar 2026 | |||
| NRIX | Nurix Therapeutics, Inc. | Director | 19 May 2025 |
Insider Transactions Reported by Roy D. Baynes:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.